1-10 of 10
Mark J. O'Connor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1

Available to Purchase
Anna D. Staniszewska, Domenic Pilger, Sonja J. Gill, Kunzah Jamal, Natacha Bohin, Sofia Guzzetti, Jacob Gordon, Gregory Hamm, Gill Mundin, Giuditta Illuzzi, Andy Pike, Lisa McWilliams, Gareth Maglennon, Jonathan Rose, Glen Hawthorne, Miguel Cortes Gonzalez, Christer Halldin, Peter Johnström, Magnus Schou, Susan E. Critchlow, Stephen Fawell, Jeffrey W. Johannes, Elisabetta Leo, Barry R. Davies, Sabina Cosulich, Jann N. Sarkaria, Mark J. O'Connor, Petra Hamerlik
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1338–1351.
https://doi.org/10.1158/1078-0432.CCR-23-2094
Published: 01 April 2024
View articletitled, Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Open the PDF for Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1 in another window
Includes: Supplementary data
Journal Articles

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper

Open Access
Giuditta Illuzzi, Anna D. Staniszewska, Sonja J. Gill, Andy Pike, Lisa McWilliams, Susan E. Critchlow, Anna Cronin, Stephen Fawell, Glen Hawthorne, Kunzah Jamal, Jeffrey Johannes, Emilyanne Leonard, Ruth Macdonald, Gareth Maglennon, Jenni Nikkilä, Mark J. O'Connor, Aaron Smith, Harriet Southgate, Joanne Wilson, James Yates, Sabina Cosulich, Elisabetta Leo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4724–4736.
https://doi.org/10.1158/1078-0432.CCR-22-0301
Published: 01 November 2022
View articletitled, Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Open the PDF for Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper in another window
Includes: Supplementary data
Journal Articles

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Open Access
Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkilä, Zena Wilson, Adina Hughes, Paul W.G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquin Arribas, Javier Cortés, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmaña, Mark J. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4536–4550.
https://doi.org/10.1158/1078-0432.CCR-22-0568
Published: 14 October 2022
View articletitled, Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Open the PDF for Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

Free
Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, Mark J. O'Connor, Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3759–3771.
https://doi.org/10.1158/1078-0432.CCR-18-0968
Published: 01 July 2019
View articletitled, PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Open the PDF for PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers in another window
Journal Articles

The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer

Free
Alice Lallo, Kristopher K. Frese, Christopher J. Morrow, Robert Sloane, Sakshi Gulati, Maximillian W. Schenk, Francesca Trapani, Nicole Simms, Melanie Galvin, Stewart Brown, Cassandra L. Hodgkinson, Lynsey Priest, Adina Hughes, Zhongwu Lai, Elaine Cadogan, Garima Khandelwal, Kathryn L. Simpson, Crispin Miller, Fiona Blackhall, Mark J. O'Connor, Caroline Dive
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (20): 5153–5164.
https://doi.org/10.1158/1078-0432.CCR-17-2805
Published: 15 October 2018
View articletitled, The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
Open the PDF for The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Free
Stephanie Lheureux, Zhongwu Lai, Brian A. Dougherty, Sarah Runswick, Darren R. Hodgson, Kirsten M. Timms, Jerry S. Lanchbury, Stan Kaye, Charlie Gourley, David Bowtell, Elise C. Kohn, Claire Scott, Ursula Matulonis, Tony Panzarella, Katherine Karakasis, Julia V. Burnier, C. Blake Gilks, Mark J. O'Connor, Jane D. Robertson, Jonathan Ledermann, J. Carl Barrett, Tony W. Ho, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4086–4094.
https://doi.org/10.1158/1078-0432.CCR-16-2615
Published: 01 August 2017
View articletitled, Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Open the PDF for Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization in another window
Includes: Supplementary data
Journal Articles

Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment

Free
Kishan A.T. Naipal, Nicole S. Verkaik, Najim Ameziane, Carolien H.M. van Deurzen, Petra ter Brugge, Matty Meijers, Anieta M. Sieuwerts, John W. Martens, Mark J. O'Connor, Harry Vrieling, Jan H.J. Hoeijmakers, Jos Jonkers, Roland Kanaar, Johan P. de Winter, Maaike P. Vreeswijk, Agnes Jager, Dik C. van Gent
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (18): 4816–4826.
https://doi.org/10.1158/1078-0432.CCR-14-0571
Published: 14 September 2014
View articletitled, Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
Open the PDF for Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment in another window
Includes: Supplementary data
Journal Articles

ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation

Free
Laura Biddlestone-Thorpe, Muhammad Sajjad, Elizabeth Rosenberg, Jason M. Beckta, Nicholas C.K. Valerie, Mary Tokarz, Bret R. Adams, Alison F. Wagner, Ashraf Khalil, Donna Gilfor, Sarah E. Golding, Sumitra Deb, David G. Temesi, Alan Lau, Mark J. O'Connor, Kevin S. Choe, Luis F. Parada, Sang Kyun Lim, Nitai D. Mukhopadhyay, Kristoffer Valerie
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (12): 3189–3200.
https://doi.org/10.1158/1078-0432.CCR-12-3408
Published: 13 June 2013
View articletitled, ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Open the PDF for ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation in another window
Includes: Supplementary data
Journal Articles

Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts

Free
Ursula Kortmann, Jessica N. McAlpine, Hui Xue, Jun Guan, Gavin Ha, Sophie Tully, Sharaz Shafait, Alan Lau, Aaron N. Cranston, Mark J. O'Connor, David G. Huntsman, Yuzhuo Wang, C. Blake Gilks
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 783–791.
https://doi.org/10.1158/1078-0432.CCR-10-1382
Published: 15 February 2011
View articletitled, Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
Open the PDF for Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts in another window
Includes: Supplementary data
Journal Articles

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

Free
Bastiaan Evers, Rinske Drost, Eva Schut, Michiel de Bruin, Eline van der Burg, Patrick W.B. Derksen, Henne Holstege, Xiaoling Liu, Ellen van Drunen, H. Berna Beverloo, Graeme C.M. Smith, Niall M.B. Martin, Alan Lau, Mark J. O'Connor, Jos Jonkers
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3916–3925.
https://doi.org/10.1158/1078-0432.CCR-07-4953
Published: 16 June 2008
View articletitled, Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Open the PDF for Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin in another window